Impact of a fluoroquinolone formulary change on acquisition of quinolone-resistant gram-negative bacilli

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 24, Issue 6, 2005, Pages 405-410

  Hota, B N ^a   Pur, S ^a,b   Phillips, L ^a,b   Weinstein, R A ^a   Segreti, J ^a,b  

^a Jr Hospital of Cook County   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; ENTERIC FEEDING; FECES MICROFLORA; GRAM NEGATIVE BACTERIUM; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; NURSING HOME; PRIORITY JOURNAL; RISK FACTOR;

ANTI-BACTERIAL AGENTS; CARRIER STATE; DRUG RESISTANCE, BACTERIAL; FECES; FLUOROQUINOLONES; FORMULARIES, HOSPITAL; GRAM-NEGATIVE AEROBIC BACTERIA; HUMANS; INTENSIVE CARE UNITS; RISK FACTORS;

EID: 21644466949     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-005-1344-4     Document Type: Article

References (20)

1. Kresken M, Wiedemann B (1988) Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin. Antimicrob Agents Chemother 32:1285-1288
2. Muder RR, Brennen C, Goetz AM, Wagener MM, Rihs JD (1991) Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs Medical Center. Antimicrob Agents Chemother 35:256-258
3. Richard P, Delangle MH, Merrien D, Barille S, Reynaud A, Minozzi C, Richet H. (1994) Fluoroquinolone use and fluoroquinolone resistance: is there an association? Clin Infect Dis 19:54-59
4. Richard P, Delangle MH, Raffi F, Espaze E, Richet H (2001) Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora. Clin Infect Dis 32:162-166
5. MacGowan AP, Wootton M, Holt HA (1999) The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility. J Antimicrob Chemother 43:345-349
6. Barry AL, Fuchs PC (1991) Cross-resistance and cross-susceptibility between fluoroquinolone agents. Eur J Clin Microbiol Infect Dis 10:1013-1018
7. Thomson KS, Sanders CC (1994) Dissociated resistance among fluoroquinolones. Antimicrob Agents Chemother 38:2095-2100
8. Dholakia N, Rolston KV, Ho DH, LeBlanc B, Bodey GP (1994) Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones. Antimicrob Agents Chemother 38:848-852
9. Scheld WM (2003) Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 9:1-9
10. Edlund C, Sjostedt S, Nord CE (1997) Comparative effects of levofloxacin and ofloxacin on the normal oral and intestinal microflora. Scand J Infect Dis 29:383-386
11. Nord CE (1995) Effect of quinolones on the human intestinal microflora. Drugs 49 (Suppl 2):81-85
12. van de Leur JJ, Vollaard EJ, Janssen AJ, Dofferhoff AS (1997) Influence of low dose ciprofloxacin on microbial colonization of the digestive tract in healthy volunteers during normal and during impaired colonization resistance. Scand J Infect Dis 29:297-300
13. Peterson LR, Postelnick M, Pozdol TL, Reisberg B, Noskin GA (1998) Management of fluoroquinolone resistance in Pseudomonas aeruginosa-outcome of monitored use in a referral hospital. Int J Antimicrob Agents 10:207-214
14. Kleinbaum DG, Kupper LL, Muller KE, Nizam A (1998) Poisson regression analysis. In: Kleinbaum DG, Kupper LL, Muller KE, Nizam A: Applied regression analysis and other multivariable methods, 3rd edn. Duxbury Press, Pacific Grove, CA, pp 687-709
15. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP (2003) Antibiotic resistance among gram-negative bacilli in U.S. intensive care units: implications for fluoroquinolone use. JAMA 289:885-888
16. Segreti J, Connelly R (1995) Effect of quinolone use on antimicrobial susceptibility patterns over a 5-year period. Drugs 49 (Suppl 2):185-187
17. Piddock L (1999) Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs 58 (Suppl 2):11-18
18. Cohen SP, McMurry LM, Hooper DC, Wolfson JS, Levy SB (1989) Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrob Agents Chemother 33:1318-1325
19. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO (2001) Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 33:1288-1294
20. Masuda N, Ohya S (1992) Cross-resistance to meropenem, cephems, and quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother 36:1847-1851